We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

131 hedge funds and large institutions have $447M invested in Rigel Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 20

100% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 15

12% more funds holding

Funds holding: 117 → 131 (+14)

6% more call options, than puts

Call options by funds: $831K | Put options by funds: $782K

0.25% more ownership

Funds ownership: 9.41% → 9.65% (+0.25%)

9% less capital invested

Capital invested by funds: $490M → $447M (-$43.5M)

Holders
131
Holders Change
+14
Holders Change %
+11.97%
% of All Funds
3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
58
Reduced
20
Closed
15
Calls
$831K
Puts
$782K
Net Calls
+$49K
Net Calls Change
-$3.66M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$10.7M
2
State Street
State Street
Massachusetts
+$10.7M
3
TA
Tamarack Advisers
California
+$9.34M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.71M
5
BlackRock
BlackRock
New York
+$8.23M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$18.4M
2
BC
Boxer Capital
California
-$10M
3
BBA
Baker Bros. Advisors
New York
-$5.26M
4
JGC
J. Goldman & Co
New York
-$2.95M
5
DCM
DAFNA Capital Management
California
-$2.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Stonepine Capital Management
Oregon
$4.24M +$5.33M +149,659 New
Morgan Stanley
27
Morgan Stanley
New York
$4.1M +$2.66M +74,793 +107%
JP Morgan Chase
28
JP Morgan Chase
New York
$3.99M -$2.18M -61,319 -30%
SCM
29
Sio Capital Management
New York
$3.96M +$4.98M +139,862 New
AllianceBernstein
30
AllianceBernstein
Tennessee
$3.3M +$1.75M +49,100 +73%
BBA
31
Baker Bros. Advisors
New York
$2.95M -$5.26M -147,727 -59%
Citigroup
32
Citigroup
New York
$2.59M -$265K -7,441 -8%
CS
33
Credit Suisse
Switzerland
$2.5M +$2.56M +71,914 +442%
State of New Jersey Common Pension Fund D
34
State of New Jersey Common Pension Fund D
New Jersey
$2.41M – – –
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2.11M -$32.5K -914 -1%
CM
36
Crestline Management
Texas
$1.88M +$1.26M +35,453 +114%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.87M +$1.87M +52,651 +394%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$1.82M -$634K -17,808 -22%
Barclays
39
Barclays
United Kingdom
$1.66M -$1.22M -34,156 -37%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.56M -$1.18M -33,081 -38%
PVI
41
Pura Vida Investments
New York
$1.56M -$123K -3,456 -6%
Allianz Asset Management
42
Allianz Asset Management
Germany
$1.29M -$9.18K -258 -0.6%
WMSA
43
Weiss Multi-Strategy Advisers
New York
$1.28M +$644K +18,110 +67%
UOC
44
UBS O'Connor
Illinois
$1.27M +$1.6M +45,000 New
ARTA
45
A.R.T. Advisors
New York
$1.21M +$1.25M +35,156 +464%
USAA
46
United Services Automobile Association
Texas
$1.12M +$58.4K +1,640 +4%
IBT
47
International Biotechnology Trust
United Kingdom
$1.04M – – –
Charles Schwab
48
Charles Schwab
California
$1.01M +$197K +5,530 +18%
Bank of America
49
Bank of America
North Carolina
$950K +$143K +4,013 +14%
TCIM
50
TIAA CREF Investment Management
New York
$948K +$28.5K +802 +2%
1
2
3 4 5

RIGL Hedge Fund Activity: Q2 2018 in Review

131 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2018, worth a combined $447M — down 8.9% from $490M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new RIGL positions and 15 closed out — a net gain of 15 holders — while 58 added to existing stakes and 20 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $10.7M. The largest seller was Great Point Partners, cutting an estimated $18.4M.

  • 131 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2018, up from 117 in Q1 2018.
  • Funds reported $447M of Rigel Pharmaceuticals stock for Q2 2018, down 8.9% quarter-over-quarter.
  • 30 funds opened new Rigel Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of +15 holders.
  • The largest Rigel Pharmaceuticals buyer in Q2 2018 was Citadel Advisors, an estimated $10.7M added.
  • The largest Rigel Pharmaceuticals seller in Q2 2018 was Great Point Partners, an estimated $18.4M sold.

Based on aggregated 13F filings for Q2 2018.